Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT

Molecular and Cellular Endocrinology

Volumn 331, Issue 1, 2011, Pages 158-167

  Hevir, Neli ^a   Šinkovec, Jasna ^b   Rižner, Tea Lanišnik ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Catechol O methyltransferase; Cytochrome P450 1B1 (CYP1B1); Endometrial cancer; Estrogen metabolizing enzymes

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; ESTROGEN; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE P1; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1E1; SULFOTRANSFERASE 2B1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; EPITHELIUM CELL; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CATECHOL O-METHYLTRANSFERASE; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; HYDROXYLATION; ISOENZYMES; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MIDDLE AGED; SULFOTRANSFERASES;

EID: 78149413899     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.09.011     Document Type: Article

References (53)

1. Adjei A.A., Weinshilboum R.M. Catecholestrogen sulfation: possible role in carcinogenesis. Biochem. Biophys. Res. Commun. 2002, 292:402-408.
2. Adjei A.A., Thomae B.A., Prondzinski J.L., Eckloff B.W., Wieben E.D., Weinshilboum R.M. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br. J. Pharmacol. 2003, 139:1373-1382.
3. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I. Endometrial cancer. Lancet 2005, 366:491-505.
4. Bai H.W., Shim J.Y., Yu J., Zhu B.T. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem. Res. Toxicol. 2007, 20:1409-1425.
5. Berstein L.M., Tchernobrovkina A.E., Gamajunova V.B., Kovalevskij A.J., Vasilyev D.A., Chepik O.F., Turkevitch E.A., Tsyrlina E.V., Maximov S.J., Ashrafian L.A., Thijssen J.H. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J. Cancer Res. Clin. Oncol. 2003, 129:245-249.
6. Bochkareva N.V., Kolomiets L.A., Kondakova I.V. Co-occurrence of hyperplasia, endometrial carcinoma and uterine myoma: role of sex hormones, their receptors and enzymes of estrogen metabolism. Vopr. Onkol. 2005, 51:427-433.
7. Bolton J.L., Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 2008, 21:93-101.
8. Butterworth M., Lau S.S., Monks T.J. Formation of catechol estrogen glutathione conjugates and gamma-glutamyl transpeptidase-dependent nephrotoxicity of 17beta-estradiol in the golden Syrian hamster. Carcinogenesis 1997, 18:561-567.
9. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
10. Cavalieri E., Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann. N. Y. Acad. Sci. 2006, 1089:286-301.
11. Cavalieri E., Chakravarti D., Guttenplan J., Hart E., Ingle J., Jankowiak R., Muti P., Rogan E., Russo J., Santen R., Sutter T. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766:63-78.
12. Chan Q.K., Khoo U.S., Chan K.Y., Ngan H.Y., Li S.S., Chiu P.M., Man L.S., Ip P.P., Xue W.C., Cheung A.N. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J. Mol. Diagn. 2005, 7:8-16.
13. Cheng Z., Rios G.R., King C.D., Coffman B.L., Green M.D., Mojarrabi B., Mackenzie P.I., Tephly T.R. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol. Sci. 1998, 45:52-57.
14. Guillemette C., Belanger A., Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res. 2004, 6:246-254.
15. Hecht J.L., Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006, 24:4783-4791.
16. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433.
17. Hirata H., Hinoda Y., Okayama N., Suehiro Y., Kawamoto K., Kikuno N., Rabban J.T., Chen L.M., Dahiya R. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008, 112:1964-1973.
18. Ito K. Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J. Exp. Med. 2007, 212:1-12.
19. Jeffery D.R., Roth J.A. Purification and kinetic mechanism of human brain soluble catechol-O-methyltransferase. J. Neurochem. 1985, 44:881-885.
20. Joosten H.F., van Acker F.A., van den Dobbelsteen D.J., Horbach G.J., Krajnc E.I. Genotoxicity of hormonal steroids. Toxicol. Lett. 2004, 151:113-134.
21. Lanisnik Rizner T. Estrogen metabolism and action in endometriosis. Mol. Cell. Endocrinol. 2009, 307:8-18.
22. Lee A.J., Cai M.X., Thomas P.E., Conney A.H., Zhu B.T. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003, 144:3382-3398.
23. Lepine J., Bernard O., Plante M., Tetu B., Pelletier G., Labrie F., Belanger A., Guillemette C. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J. Clin. Endocrinol. Metab. 2004, 89:5222-5232.
24. Lepine J., Audet-Walsh E., Gregoire J., Tetu B., Plante M., Menard V., Ayotte P., Brisson J., Caron P., Villeneuve L., Belanger A., Guillemette C. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J. Clin. Endocrinol. Metab. 2010, 95:2689-2698.
25. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr. Rev. 2000, 21:40-54.
26. Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan J. Obstet. Gynecol. 2007, 46:26-32.
27. Lo H.W., Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr. Opin. Pharmacol. 2007, 7:367-374.
28. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
29. Mannisto P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
30. Nebert D.W. Elevated estrogen 16 alpha-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk?. J. Natl. Cancer Inst. 1993, 85:1888-1891.
31. Neves M.A., Dinis T.C., Colombo G., Luisa Sa E.M.M. Biochemical and computational insights into the anti-aromatase activity of natural catechol estrogens. J. Steroid Biochem. Mol. Biol. 2008, 110:10-17.
32. Nieminen T.T., Gylling A., Abdel-Rahman W.M., Nuorva K., Aarnio M., Renkonen-Sinisalo L., Jarvinen H.J., Mecklin J.P., Butzow R., Peltomaki P. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin. Cancer Res. 2009, 15:5772-5783.
33. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
34. Parl F.F., Egan K.M., Li C., Crooke P.S. Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction. Cancer Inform. 2009, 7:109-121.
35. Pasqualini J.R., Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 2005, 93:221-236.
36. Pihlavisto P., Reenila I. Separation methods for catechol O-methyltransferase activity assay: physiological and pathophysiological relevance. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2002, 781:359-372.
37. Raftogianis R., Creveling C., Weinshilboum R., Weisz J. Estrogen metabolism by conjugation. J. Natl. Cancer Inst. Monogr. 2000, 113-124. (Chapter 6).
38. Salama S.A., Kamel M., Awad M., Nasser A.H., Al-Hendy A., Botting S., Arrastia C. Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase. Int. J. Cancer 2008, 123:1246-1254.
39. Saini S., Hirata H., Majid S., Dahiya R. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res. 2009, 69:7038-7045.
40. Sanchez R.I., Mesia-Vela S., Kauffman F.C. Induction of NAD(P)H quinone oxidoreductase and glutathione S-transferase activities in livers of female August-Copenhagen Irish rats treated chronically with estradiol: comparison with the Sprague-Dawley rat. J. Steroid Biochem. Mol. Biol. 2003, 87:199-206.
41. Sasaki M., Kaneuchi M., Fujimoto S., Tanaka Y., Dahiya R. CYP1B1 gene in endometrial cancer. Mol. Cell. Endocrinol. 2003, 202:171-176.
42. Sasaki M., Kaneuchi M., Sakuragi N., Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 2003, 63:3101-3106.
43. Samarnthai N., Hall K., Yeh I.T. Molecular profiling of endometrial malignancies. Obstet. Gynecol. Int. 2010, 2010:162363.
44. Singh M.N., Stringfellow H.F., Walsh M.J., Ashton K.M., Paraskevaidis E., Abdo K.R., Martin-Hirsch P.L., Phillips D.H., Martin F.L. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology 2008, 249:85-90.
45. Tenhunen J., Salminen M., Lundstrom K., Kiviluoto T., Savolainen R., Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 1994, 223:1049-1059.
46. Terrier P., Townsend A.J., Coindre J.M., Triche T.J., Cowan K.H. An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am. J. Pathol. 1990, 137:845-853.
47. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. (RESEARCH0034).
48. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr. 2000, 67-73.
49. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 2006, 354:270-282.
50. Zhu B.T., Liehr J.G. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J. Biol. Chem. 1996, 271:1357-1363.
51. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19:1-27.
52. Zhu B.T., Lee A.J. NADPH-dependent metabolism of 17beta-estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. Steroids 2005, 70:225-244.
53. Zhu B.T., Han G.Z., Shim J.Y., Wen Y., Jiang X.R. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 2006, 147:4132-4150.